Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (DASAPOST)
Read time: 1 mins
Last updated:27th Feb 2013
Trial try to assess the efficacy of dasatinib in terms of major molecular response rate at 6 months in patients with CP-CML who have achieved complete cytogenetic response without major molecular response after at least 18 months on Imatinib 400/600.
|Study start date||2013-02-27|